Clinical & Preclinical Studies on BPC-157 Explained
BPC-157 has one of the most extensive preclinical research records of any peptide outside of pharmaceutical development. Professor Slobodan Sikiric's laboratory at the University of Zagreb has produced over 100 published papers on BPC-157 since 1993. This article maps the key studies by tissue type, covers the human clinical data that exists, and explains how to honestly evaluate the evidence.
Virtually all of the foundational BPC-157 research comes from Professor Slobodan Sikiric and his team at the University of Zagreb School of Medicine in Croatia. This concentration of research in a single lab is both a strength (deep, systematic investigation of a single compound) and a limitation (independent replication is more limited than ideal).
Sikiric's lab has published in respected international journals including Journal of Orthopaedic Research, Regulatory Peptides, Digestive Diseases and Sciences, and Neuroscience. The research is peer-reviewed and methodologically consistent. Independent research groups have begun replicating findings, particularly for the gut and tendon applications.
Studies by Tissue Type
Tendon & Ligament
J Orthop Res
First published evidence of BPC-157 accelerating Achilles tendon healing in rat transection model. Faster fibroblast infiltration and collagen organisation vs control.
J Physiol Pharmacol
BPC-157 promoted tendon-to-bone healing in rotator cuff injury models, with significantly greater mechanical load tolerance at 4 weeks.
Inflammopharmacology
Lateral collateral ligament healing study — treated ligaments showed near-normal collagen architecture at 4 weeks vs disordered scar tissue in controls.
Muscle
Regul Pept
BPC-157 accelerated healing of surgically created muscle crush injuries. Faster regeneration of myofibrils and reduced inflammatory infiltration at treated sites.
Eur J Pharmacol
Complete muscle transection model — BPC-157 treated rats recovered functional strength significantly faster. Muscle remodelling was qualitatively superior at the histological level.
Gut / GI Tract
Dig Dis Sci
Oral BPC-157 reduced NSAID-induced gastric ulcer severity by 50% vs placebo in rat models. Maintained mucosal integrity and reduced inflammatory markers.
J Physiol Paris
IBD model — BPC-157 significantly reduced colonic inflammation scores, improved tight junction integrity, and preserved villous structure in colitis-induced rats.
World J Gastroenterol
Cytoprotective effects in intestinal anastomotic healing — BPC-157 reduced anastomotic leak rate and improved wound tensile strength.
Bone & Cartilage
Bone
BPC-157 accelerated fracture healing in rat femoral fracture models — earlier callus formation, faster mineralisation, greater bone density at fracture site vs controls.
Knee Surg Sports Traumatol Arthrosc
Articular cartilage repair study — BPC-157 treated defects showed improved proteoglycan content and chondrocyte density vs untreated controls.
Nerve & Brain
Regul Pept
Peripheral nerve crush injury model — BPC-157 produced faster axonal regeneration and functional recovery (measured by toe spread and muscle electromyography) than controls.
Neuroscience
Traumatic brain injury model — BPC-157 reduced neurological deficit scores, improved brain lesion size, and attenuated post-injury dopamine depletion.
The most advanced human data for BPC-157 is the PL-10 program — oral BPC-157 for inflammatory bowel disease. This represents the compound in its most bioavailable form for its most direct application (gut mucosal healing).
PL-10 Phase 2 IBD Trial
- • Oral BPC-157 in tablet form for Crohn's disease and ulcerative colitis
- • Phase 2 trials conducted — safety profile confirmed in human patients
- • Efficacy results consistent with animal model predictions
- • No large Phase 3 RCT has been completed or published as of 2026
- • The compound is not FDA-approved; development has not advanced commercially
For musculoskeletal applications — tendon, ligament, muscle — there are no completed human clinical trials. All efficacy data for these applications is extrapolated from animal models.
The BPC-157 evidence base is among the strongest available for a non-pharmaceutical research peptide. That said, honest evaluation requires understanding what animal studies do and don't tell you:
Rodents heal faster than humans
A 'full recovery' in a rat Achilles model at 4 weeks doesn't mean 4-week human Achilles recovery. Scale effects are real.
Intraperitoneal (IP) injection ≠ subcutaneous injection
Most animal studies use IP injection, which produces different bioavailability to SubQ injection used by human researchers.
Dose scaling is uncertain
Converting rodent doses to human equivalents involves body surface area calculations that are imprecise. The doses used in human research are informed estimates, not validated protocols.
Publication bias likely exists
Positive results are more publishable. The absence of negative findings in the BPC-157 literature partly reflects a publishing environment that doesn't prioritise null results.
BPC-157 — Research Grade
Available from Base Peptides with third-party certificate of analysis.
All BPC-157 Guides
Other Articles
Calculator
Calculate exact reconstitution volumes and insulin unit doses for any peptide protocol.
Open Calculator →